Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Massange-Snchez et al., 2016)
Although Bcr-Abl inhibitors such as imatinib, nilotinib, and dasatinib are effective in CML therapy 7,8,9 , the acquisition of the T315I mutation of BCR-ABL in patients causes the resistance to most tyrosine kinase inhibitors (TKI), leading to poor outcomes
In mice treated with a combination of TMQ0153, venetoclax, and azacitidine induced no significant weight loss (below 17% on day 10 and 14% on day13 of the relative body weight for vehicle animals) (Fig
had a history of mechanical or chemical corneal trauma
This work was also supported by the Einstein-Sinai Diabetes Research Center (P30DK20541)
US$ 21.58
US$ 24.65
US$ 23.06
US$ 26.59
US$ 22.36
US$ 28.02
US$ 26.61
US$ 20.80
US$ 24.26
